Review Article
Free Access
Application of MRS to mouse models of neurodegenerative illness
Ji-Kyung Choi,
Alpaslan Dedeoglu,
Bruce G. Jenkins,
Ji-Kyung Choi
Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
Search for more papers by this authorAlpaslan Dedeoglu
Department of Neurology, Boston University School of Medicine, Bedford VA Medical Center, Bedford, MA, USA
Search for more papers by this authorCorresponding Author
Bruce G. Jenkins
Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
Building 149, 13th Street, Charlestown, MA 02129, USA.Search for more papers by this author
Ji-Kyung Choi,
Alpaslan Dedeoglu,
Bruce G. Jenkins,
Ji-Kyung Choi
Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
Search for more papers by this authorAlpaslan Dedeoglu
Department of Neurology, Boston University School of Medicine, Bedford VA Medical Center, Bedford, MA, USA
Search for more papers by this authorCorresponding Author
Bruce G. Jenkins
Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
Building 149, 13th Street, Charlestown, MA 02129, USA.Search for more papers by this authorAbstract
The rapid development of transgenic mouse models of neurodegenerative diseases, in parallel with the rapidly expanding growth of MR techniques for assessing in vivo, non-invasive, neurochemistry, offers the potential to develop novel markers of disease progression and therapy. In this review we discuss the interpretation and utility of MRS for the study of these transgenic mouse and rodent models of neurodegenerative diseases such as Alzheimer's (AD), Huntington's (HD) and Parkinson's disease (PD). MRS studies can provide a wealth of information on various facets of in vivo neurochemistry, including neuronal health, gliosis, osmoregulation, energy metabolism, neuronal–glial cycling, and molecular synthesis rates. These data provide information on the etiology, natural history and therapy of these diseases. Mouse models enable longitudinal studies with useful time frames for evaluation of neuroprotection and therapeutic interventions using many of the potential MRS markers. In addition, the ability to manipulate the genome in these models allows better mechanistic understanding of the roles of the observable neurochemicals, such as N-acetylaspartate, in the brain. The argument is made that use of MRS, combined with correlative histology and other MRI techniques, will enable objective markers with which potential therapies can be followed in a quantitative fashion. Copyright © 2007 John Wiley & Sons, Ltd.
REFERENCES
- 1 MacDonald ME, Gusella JF. Huntington's disease: translating a CAG repeat into a pathogenic mechanism. Curr Opin Neurobiol 1996; 6: 638–643.
- 2 Ordway JM, Tallaksen-Greene S, Gutekunst CA, Bernstein EM, Cearley JA, Wiener HW, Dure LSt, Lindsey R, Hersch SM, Jope RS, Albin RL, Detloff PJ. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 1997; 91: 753–763.
- 3 Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004; 10 Suppl: S2–9.
- 4 Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000; 10: 524–530.
- 5 Ross CA, Poirier MA. Opinion: What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 2005; 6: 891–898.
- 6 Schulz JB, Dichgans J. Molecular pathogenesis of movement disorders: are protein aggregates a common link in neuronal degeneration? Curr Opin Neurol 1999; 12: 433–439.
- 7 Fisher M. Potentially effective therapies for acute ischemic stroke. Eur Neurol 1995; 35: 3–7.
- 8 Hossmann KA. Glutamate-mediated injury in focal cerebral ischemia: the excitotoxin hypothesis revised. Brain Pathol 1994; 4: 23–36.
- 9 Hossmann KA. Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol 2006.
- 10 Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen HC, Germeyer A, Steiner SM, Bruce-Keller AJ, Hutchins JB, Mattson MP. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci 1998; 18: 687–697.
- 11 Kogure T, Kogure K. Molecular and biochemical events within the brain subjected to cerebral ischemia (targets for therapeutical intervention). Clin Neurosci 1997; 4: 179–183.
- 12 Siesjo BK. Pathophysiology and treatment of focal cerebral ischemia. Part II: Mechanisms of damage and treatment. J Neurosurg 1992; 77: 337–354.
- 13 Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 1994; 36: 882–888.
- 14 B Jenkins, Y Chen, B Rosen (eds). Investigating the neurochemistry and etiology of neurodegenrative disorders using magnetic resonance spectroscopy. Wiley-Liss: New York, 1997.
- 15 Jenkins BG, Brouillet E, Chen YC, Storey E, Schulz JB, Kirschner P, Beal MF, Rosen BR. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 1996; 16: 450–461.
- 16 Blass JP, Sheu RK, Cedarbaum JM. Energy metabolism in disorders of the nervous system. Rev Neurol 1988; 144: 543–563.
- 17 Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH, Wu YC, Sun CN, Chien CL, Lin YS, Wang SC, Tung YY, Chang C, Chern Y. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem 2005; 93: 310–320.
- 18 Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF. Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 2001; 8: 479–491.
- 19 Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000; 20: 4389–4397.
- 20 Choi IY, Lee SP, Guilfoyle DN, Helpern JA. In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models. Neurochem Res 2003; 28: 987–1001.
- 21 Hilal SK, Maudsley AA, Simon HE, Perman WH, Bonn J, Mawad ME, Silver AJ, Ganti SR, Sane P, Chien IC. In vivo NMR imaging of tissue sodium in the intact cat before and after acute cerebral stroke. AJNR Am J Neuroradiol 1983; 4: 245–249.
- 22 Kalyanapuram R, Seshan V, Bansal N. Three-dimensional triple-quantum-filtered 23Na imaging of the dog head in vivo. J Magn Reson Imaging 1998; 8: 1182–1189.
- 23 Lin SP, Song SK, Miller JP, Ackerman JJ, Neil JJ. Direct, longitudinal comparison of (1)H and (23)Na MRI after transient focal cerebral ischemia. Stroke 2001; 32: 925–932.
- 24 Thulborn KR, Gindin TS, Davis D, Erb P. Comprehensive MR imaging protocol for stroke management: tissue sodium concentration as a measure of tissue viability in nonhuman primate studies and in clinical studies. Radiology 1999; 213: 156–166.
- 25 Pfeuffer J, Tkac I, Provencher SW, Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J Magn Reson 1999; 141: 104–120.
- 26 Tkac I, Andersen P, Adriany G, Merkle H, Ugurbil K, Gruetter R. In vivo1H NMR spectroscopy of the human brain at 7 T. Magn Reson Med 2001; 46: 451–456.
- 27 Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989; 11: 47–63.
- 28 Behar KL, Ogino T. Assignment of resonances in the 1H spectrum of rat brain by two- dimensional shift correlated and J-resolved NMR spectroscopy. Magn. Reson. Med. 1991; 17: 285–303.
- 29 Behar KL, Ogino T. Characterization of macromolecule resonances in the 1H NMR spectrum of rat brain. Magn Reson Med 1993; 30: 38–44.
- 30 Birken DL, Oldendorf WH. N-Acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci. Biobehav Rev. 1989; 13: 23–31.
- 31 Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37–45.
- 32 Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocyte- type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 1992; 59: 55–61.
- 33 Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993; 13: 981–989.
- 34 Hetherington HP, Pan JW, Mason GF, Adams D, Vaughn MJ, Twieg DB, Pohost GM. Quantitative 1H spectroscopic imaging of human brain at 4.1 T using image segmentation. Magn Reson Med 1996; 36: 21–29.
- 35 Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD. Probable Alzheimer disease: diagnosis with proton MR spectroscopy [see comments]. Radiology 1995; 195: 65–72.
- 36 Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 1993; 43: 2689–2695.
- 37 Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, Koroshetz WJ. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 1998; 50: 1357–1365.
- 38 Dunlop DS, Mc Hale DM, Lajtha A. Decreased brain N-acetylaspartate in Huntington's disease. Brain Res 1992; 580: 44–48.
- 39 Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 2000; 74: 2108–2119.
- 40 De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995; 34: 721–727.
- 41 Mathews PM, Andermann F, Silver K, Karpati G, Arnold DL. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology 1993; 43: 2484–2490.
- 42 Fenstermacher MJ, Narayana PA. Serial proton magnetic resonance spectroscopy of ischemic brain injury in humans. Invest Radiol 1990; 25: 1034–1039.
- 43 Higuchi T, Fernandez EJ, Maudsley AA, Shimizu H, Weiner MW, Weinstein PR. Mapping of lactate and N-acetyl-L-aspartate predicts infarction during acute focal ischemia: in vivo1H magnetic resonance spectroscopy in rats. Neurosurgery 1996; 38: 121–129; discussion 129–130.
- 44 Saunders DE. MR spectroscopy in stroke. Br Med Bull 2000; 56: 334–345.
- 45 Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, McDonald WI. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49–58.
- 46 De Stefano N, Matthews PM, Narayanan S, Francis GS, Antel JP, Arnold DL. Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology 1997; 49: 1138–1141.
- 47 Kuzniecky R, Palmer C, Hugg J, Martin R, Sawrie S, Morawetz R, Faught E, Knowlton R. Magnetic resonance spectroscopic imaging in temporal lobe epilepsy: neuronal dysfunction or cell loss? Arch Neurol 2001; 58: 2048–2053.
- 48 Petroff OA, Errante LD, Rothman DL, Kim JH, Spencer DD. Neuronal and glial metabolite content of the epileptogenic human hippocampus. Ann Neurol 2002; 52: 635–642.
- 49 Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, Ross CA, Ferrante RJ, Beal MF. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J Neurochem 2005; 95: 553–562.
- 50 Taylor DL, Davies SE, Obrenovitch TP, Doheny MH, Patsalos PN, Clark JB, Symon L. Investigation into the role of N-acetylaspartate in cerebral osmoregulation. J Neurochem 1995; 65: 275–281.
- 51 Baslow MH. Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review. Neurochem Int 2002; 40: 295–300.
- 52 Baslow MH. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation. J Mol Neurosci 2003; 21: 185–190.
- 53 Choi IY, Gruetter R. Dynamic or inert metabolism? Turnover of N-acetyl aspartate and glutathione from D-[1-13C]glucose in the rat brain in vivo. J Neurochem 2004; 91: 778–787.
- 54 Karelson G, Ziegler A, Kunnecke B, Seelig J. Feeding versus infusion: a novel approach to study the NAA metabolism in rat brain. NMR Biomed 2003; 16: 413–423.
- 55 Moreno A, Ross BD, Bluml S. Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by (13)C MRS and [1-(13)C]glucose infusion. J Neurochem 2001; 77: 347–350.
- 56 Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998; 9: 1757–1761.
- 57 Prichard J, Rothman D, Novotny E, Petroff O, Kuwabara T, Avison M, Howseman A, Hanstock C, Shulman R. Lactate rise detected by 1H NMR in human visual cortex during physiologic stimulation. Proc Natl Acad Sci USA 1991; 88: 5829–5831.
- 58 Schurr A, West CA, Rigor BM. Lactate-supported synaptic function in the rat hippocampal slice preparation. Science 1988; 240: 1326–1328.
- 59 Magistretti PJ, Pellerin L. Regulation by neurotransmitters of glial energy metabolism. Adv Exp Med Biol 1997; 429: 137–143.
- 60 Petroff OA, Graham GD, Blamire AM, al-Rayess M, Rothman DL, Fayad PB, Brass LM, Shulman RG, Prichard JW. Spectroscopic imaging of stroke in humans: histopathology correlates of spectral changes. Neurology 1992; 42: 1349–1354.
- 61 Dager SR, Strauss WL, Marro KI, Richards TL, Metzger GD, Artru AA. Proton magnetic resonance spectroscopy investigation of hyperventilation in subjects with panic disorder and comparison subjects. Am J Psychiatry 1995; 152: 666–672.
- 62 Sotak CH, Alger JR. A pitfall associated with lactate detection using stimulated-echo proton spectroscopy. Magn Reson Med 1991; 17: 533–538.
- 63 Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999; 81: 163–221.
- 64 Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, Wellington CL, Raymond LA, Hayden MR. Wild-type huntingtin protects neurons from excitotoxicity. J Neurochem 2006; 96: 1121–1129.
- 65 Rego AC, Oliveira CR. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem Res 2003; 28: 1563–1574.
- 66 Schousboe A, Waagepetersen HS. Role of astrocytes in glutamate homeostasis: implications for excitotoxicity. Neurotox Res 2005; 8: 221–225.
- 67 Mason GF, Pan JW, Ponder SL, Twieg DB, Pohost GM, Hetherington HP. Detection of brain glutamate and glutamine in spectroscopic images at 4.1 T. Magn Reson Med 1994; 32: 142–145.
- 68 Bristol LA, Rothstein JD. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann Neurol 1996; 39: 676–679.
- 69 Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38: 73–84.
- 70 Pioro EP, Majors AW, Mitsumoto H, Nelson DR, Ng TC. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology 1999; 53: 71–79.
- 71 Andreassen OA, Jenkins BG, Dedeoglu A, Ferrante KL, Bogdanov MB, Kaddurah-Daouk R, Beal MF. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem 2001; 77: 383–390.
- 72 Tkac I, Keene CD, Pfeuffer J, Low WC, Gruetter R. Metabolic changes in quinolinic acid-lesioned rat striatum detected non-invasively by in vivo (1)H NMR spectroscopy. J Neurosci Res 2001; 66: 891–898.
- 73 Jenkins BG, Kraft E. Magnetic resonance spectroscopy in toxic encephalopathy and neurodegeneration. Curr Opin Neurol 1999; 12: 753–760.
- 74 Petroff OA, Pleban LA, Spencer DD. Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of the epileptic human brain. Magn Reson Imaging 1995; 13: 1197–1211.
- 75 Podo F. Tumour phospholipid metabolism. NMR Biomed 1999; 12: 413–439.
10.1002/(SICI)1099-1492(199911)12:7<413::AID-NBM587>3.0.CO;2-U CASPubMedWeb of Science®Google Scholar
- 76 Smith JK, Castillo M, Kwock L. MR spectroscopy of brain tumors. Magn Reson Imaging Clin N Am 2003; 11: 415–429. v–vi.
- 77 Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993; 15: 289–298.
- 78 Thurston JH, Sherman WR, Hauhart RE, Kloepper RF. myo-inositol: a newly identified nonnitrogenous osmoregulatory molecule in mammalian brain. Pediatr Res 1989; 26: 482–485.
- 79 Isaacks RE, Bender AS, Kim CY, Shi YF, Norenberg MD. Effect of ammonia and methionine sulfoximine on myo-inositol transport in cultured astrocytes. Neurochem Res 1999; 24: 51–59.
- 80 Klunk WE, Xu C, Panchalingam K, McClure RJ, Pettegrew JW. Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol Aging 1996; 17: 349–357.
- 81 Pettegrew JW, Klunk WE, Panchalingam K, McClure RJ, Stanley JA. Magnetic resonance spectroscopic changes in Alzheimer's disease. Ann N Y Acad Sci 1997; 826: 282–306.
- 82 Behar KL, Boehm D. Measurement of GABA following GABA-transaminase inhibition by gabaculine: a 1H and 31P NMR spectroscopic study of rat brain in vivo. Magn Reson Med 1994; 31: 660–667.
- 83 Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672–679.
- 84 Bartha R, Drost DJ, Williamson PC. Factors affecting the quantification of short echo in-vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed 1999; 12: 205–216.
10.1002/(SICI)1099-1492(199906)12:4<205::AID-NBM558>3.0.CO;2-1 CASPubMedWeb of Science®Google Scholar
- 85 Hwang JH, Graham GD, Behar KL, Alger JR, Prichard JW, Rothman DL. Short echo time proton magnetic resonance spectroscopic imaging of macromolecule and metabolite signal intensities in the human brain. Magn Reson Med 1996; 35: 633–639.
- 86 Marjanska M, Curran GL, Wengenack TM, Henry PG, Bliss RL, Poduslo JF, Jack CR Jr, Ugurbil K, Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 2005; 102: 11906–11910.
- 87 Marcucci F, Airoldi L, Mussini E. Brain level of N-acetyl-L-aspartate in different strains of mouse and rat. J Neurochem 1969; 16: 272–273.
- 88 Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, Gonzalez RG. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1997; 94: 6408–6413.
- 89 de Graaf RA, Brown PB, Mason GF, Rothman DL, Behar KL. Detection of [1,6-13C2]-glucose metabolism in rat brain by in vivo1H-[13C]-NMR spectroscopy. Magn Reson Med 2003; 49: 37–46.
- 90 Henry PG, Roussel R, Vaufrey F, Dautry C, Bloch G. Semiselective POCE NMR spectroscopy. Magn Reson Med 2000; 44: 395–400.
- 91 Pan JW, Stein DT, Telang F, Lee JH, Shen J, Brown P, Cline G, Mason GF, Shulman GI, Rothman DL, Hetherington HP. Spectroscopic imaging of glutamate C4 turnover in human brain. Magn Reson Med 2000; 44: 673–679.
- 92 Golman K, Ardenkjaer-Larsen JH, Petersson JS, Mansson S, Leunbach I. Molecular imaging with endogenous substances. Proc Natl Acad Sci USA 2003; 100: 10435–10439.
- 93 Golman K, Zandt RI, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 2006; 66: 10855–10860.
- 94 Badar-Goffer RS, Bachelard HS, Morris PG. Cerebral metabolism of acetate and glucose studied by 13C-n.m.r. spectroscopy. A technique for investigating metabolic compartmentation in the brain. Biochem J 1990; 266: 133–139.
- 95 Bluml S, Moreno-Torres A, Shic F, Nguy CH, Ross BD. Tricarboxylic acid cycle of glia in the in vivo human brain. NMR Biomed 2002; 15: 1–5.
- 96 Hassel B, Sonnewald U, Fonnum F. Glial-neuronal interactions as studied by cerebral metabolism of [2-13C]acetate and [1-13C]glucose: an ex vivo13C NMR spectroscopic study. J Neurochem 1995; 64: 2773–2782.
- 97 Lebon V, Petersen KF, Cline GW, Shen J, Mason GF, Dufour S, Behar KL, Shulman GI, Rothman DL. Astroglial contribution to brain energy metabolism in humans revealed by 13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. J Neurosci 2002; 22: 1523–1531.
- 98 Gruetter R, Novotny EJ, Boulware SD, Mason GF, Rothman DL, Shulman GI, Prichard JW, Shulman RG. Localized 13C NMR spectroscopy in the human brain of amino acid labeling from D-[1-13C]glucose. J Neurochem 1994; 63: 1377–1385.
- 99 Mason GF, Behar KL, Rothman DL, Shulman RG. NMR determination of intracerebral glucose concentration and transport kinetics in rat brain. J Cereb Blood Flow Metab 1992; 12: 448–455.
- 100 Mason GF, Gruetter R, Rothman DL, Behar KL, Shulman RG, Novotny EJ. Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J Cereb Blood Flow Metab 1995; 15: 12–25.
- 101 Sibson NR, Dhankhar A, Mason GF, Behar KL, Rothman DL, Shulman RG. In vivo13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling. Proc Natl Acad Sci USA 1997; 94: 2699–2704.
- 102 Van Zijl PC, Davis D, Eleff SM, Moonen CT, Parker RJ, Strong JM. Determination of cerebral glucose transport and metabolic kinetics by dynamic MR spectroscopy. Am J Physiol 1997; 273: E1216–1227.
- 103 Lin AP, Shic F, Enriquez C, Ross BD. Reduced glutamate neurotransmission in patients with Alzheimer's disease: an in vivo (13)C magnetic resonance spectroscopy study. Magma 2003; 16: 29–42.
- 104 Choi J-K, Kuestermann E, Andreassen OA, Beal MF, Jenkins BG. A tale of two mice: impaired glial-neuronal cycling in mouse models of Huntington's disease and amyotrophic lateral sclerosis. International Society of Magnetic Resonance in Medicine 11th Scientific Meeting and Exhibition. Toronto, Canada, 2003; 437.
- 105 Tyson RL, Sutherland GR. Labeling of N-acetylaspartate and N-acetylaspartylglutamate in rat neocortex, hippocampus and cerebellum from [1-13C]glucose. Neurosci Lett 1998; 251: 181–184.
- 106 Serles W, Li LM, Antel SB, Cendes F, Gotman J, Olivier A, Andermann F, Dubeau F, Arnold DL. Time course of postoperative recovery of N-acetyl-aspartate in temporal lobe epilepsy. Epilepsia 2001; 42: 190–197.
- 107 Kalra S, Arnold DL, Cashman NR. Biological markers in the diagnosis and treatment of ALS. J Neurol Sci 1999; 165 Suppl 1: S27–32.
- 108 Signoretti S, Marmarou A, Fatouros P, Hoyle R, Beaumont A, Sawauchi S, Bullock R, Young H. Application of chemical shift imaging for measurement of NAA in head injured patients. Acta Neurochir Suppl 2002; 81: 373–375.
- 109 Jenkins BG, Burns L, Pakzaban P, Chen YI, Deacon T, Rosen BR, Brillault C, Isacson I. Spectroscopic studies of neurochemical changes in a primate model of neurodegeneration and neural transplantation. Society of Magnetic Resonance 2nd Annual Meeting. San Francisco, 1994; 1423.
- 110 Ross BD, Hoang TQ, Bluml S, Dubowitz D, Kopyov OV, Jacques DB, Lin A, Seymour K, Tan J. In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed 1999; 12: 221–236.
10.1002/(SICI)1099-1492(199906)12:4<221::AID-NBM582>3.0.CO;2-Q CASPubMedWeb of Science®Google Scholar
- 111 Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, Hyman BT. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem 1993; 61: 1147–1150.
- 112 Dijkhuizen RM, van Lookeren Campagne M, Niendorf T, Dreher W, van der Toorn A, Hoehn-Berlage M, Verheul HB, Tulleken CA, Leibfritz D, Hossmann KA, Nicolay K. Status of the neonatal rat brain after NMDA-induced excitotoxic injury as measured by MRI, MRS and metabolic imaging. NMR Biomed 1996; 9: 84–92.
- 113 Henshaw R, Jenkins BG, Schulz JB, Ferrante RJ, Kowall NW, Rosen BR, Beal MF. Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res 1994; 647: 161–166.
- 114 Lee WT, Shen YZ, Chang C. Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid: evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy. Neuroscience 2000; 95: 89–95.
- 115 Storey E, Hyman BT, Jenkins B, Brouillet E, Miller JM, Rosen BR, Beal MF. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 1992; 58: 1975–1978.
- 116 Schulz JB, Henshaw DR, Siwek D, Jenkins BG, Ferrante RJ, Cipolloni PB, Kowall NW, Rosen BR, Beal MF. Involvement of free radicals in excitotoxicity in vivo. J Neurochem 1995; 64: 2239–2247.
- 117 Schulz JB, Matthews RT, Jenkins BG, Brar P, Beal MF. Improved therapeutic window for treatment of histotoxic hypoxia with a free radical spin trap. J Cereb Blood Flow Metab 1995; 15: 948–952.
- 118 Kirschner PB, Jenkins BG, Schulz JB, Finkelstein SP, Matthews RT, Rosen BR, Beal MF. NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals. Brain Res 1996; 713: 178–185.
- 119 Jenkins B, Brouillet E, Chen Y, Storey E, Schulz J, Kirschner P, Beal M, Rosen B. Non-Invasive neurochemical analysis of focal excitotoxic lesions iin models of neurodegenerative illness using spectroscopic imaging. J. Cereb. Blood Flow Metab 1996; 16: 450–461.
- 120 Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 1998; 18: 156–163.
- 121 McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006; 22: 281–289.
- 122 Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 2004; 1012: 60–65.
- 123 von Kienlin M, Kunnecke B, Metzger F, Steiner G, Richards JG, Ozmen L, Jacobsen H, Loetscher H. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 2005; 18: 32–39.
- 124 Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409–421.
- 125 Jenkins BG, Chen YI, Kuestermann E, Makris NM, Nguyen TV, Kraft E, Brownell AL, Rosas HD, Kennedy DN, Rosen BR, Koroshetz WJ, Beal MF. An integrated strategy for evaluation of metabolic and oxidative defects in neurodegenerative illness using magnetic resonance techniques [In Process Citation]. Ann N Y Acad Sci 1999; 893: 214–242.
- 126 Jack CR Jr, Wengenack TM, Reyes DA, Garwood M, Curran GL, Borowski BJ, Lin J, Preboske GM, Holasek SS, Adriany G, Poduslo JF. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci 2005; 25: 10041–10048.
- 127 Wu EX, Tang H, Asai T, Yan SD. Regional cerebral blood volume reduction in transgenic mutant APP (V717F, K670N/M671L) mice. Neurosci Lett 2004; 365: 223–227.
- 128 Hoang TQ, Bluml S, Dubowitz DJ, Moats R, Kopyov O, Jacques D, Ross BD. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998; 50: 1033–1040.
- 129 Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A, Viano J, de Yebenes JG. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology 1999; 53: 806–812.
- 130 Harms L, Meierkord H, Timm G, Pfeiffer L, Ludolph AC. Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry 1997; 62: 27–30.
- 131 Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493–506.
- 132 Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90: 537–548.
- 133 Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin [published erratum appears in Hum Mol Genet 1999 May; 8(5): 943]. Hum Mol Genet 1999; 8: 397–407.
- 134 Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999; 23: 181–192.
- 135 van Dellen A, Welch J, Dixon RM, Cordery P, York D, Styles P, Blakemore C, Hannan AJ. N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport 2000; 11: 3751–3757.
- 136 Law RO. Regulation of mammalian brain cell volume. J Exp Zool 1994; 268: 90–96.
- 137 Smith SA, Levante TO, Meier BH, Ernst RR. Computer simulations in magnetic resonance. An object oriented programming approach. J. Magn. Reson. 1994; 106a: 75–105.
- 138 Tsang TM, Woodman B, McLoughlin GA, Griffin JL, Tabrizi SJ, Bates GP, Holmes E. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. J Proteome Res 2006; 5: 483–492.
- 139 Oz G, Terpstra M, Tkac I, Aia P, Lowary J, Tuite PJ, Gruetter R. Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med 2006; 55: 296–301.
- 140 Brownell AL, Jenkins BG, Elmaleh DR, Deacon TW, Spealman RD, Isacson O. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nat Med 1998; 4: 1308–1312.
- 141 Boska MD, Lewis TB, Destache CJ, Benner EJ, Nelson JA, Uberti M, Mosley RL, Gendelman HE. Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. J Neurosci 2005; 25: 1691–1700.
- 142 Pfund Z, Chugani DC, Juhasz C, Muzik O, Chugani HT, Wilds IB, Seraji-Bozorgzad N, Moore GJ. Evidence for coupling between glucose metabolism and glutamate cycling using FDG PET and 1H magnetic resonance spectroscopy in patients with epilepsy. J Cereb Blood Flow Metab 2000; 20: 871–878.
- 143 Barbiroli B, Iotti S, Lodi R. Aspects of human bioenergetics as studied in vivo by magnetic resonance spectroscopy. Biochimie 1998; 80: 847–853.
- 144 Barbiroli B, Montagna P, Martinelli P, Lodi R, Iotti S, Cortelli P, Funicello R, Zaniol P. Defective brain energy metabolism shown by in vivo31P MR spectroscopy in 28 patients with mitochondrial cytopathies. J Cereb Blood Flow Metab 1993; 13: 469–474.
- 145 Radda GK. Control, bioenergetics, and adaptation in health and disease: noninvasive biochemistry from nuclear magnetic resonance. FASEB J 1992; 6: 3032–3038.
- 146 De Stefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995; 45: 1193–1198.
- 147 Gruetter R, Novotny EJ, Boulware SD, Rothman DL, Shulman RG. 1H NMR studies of glucose transport in the human brain. J Cereb Blood Flow Metab 1996; 16: 427–438.
- 148 Gyngell ML, Michaelis T, Horstermann D, Bruhn H, Hanicke W, Merboldt KD, Frahm J. Cerebral glucose is detectable by localized proton NMR spectroscopy in normal rat brain in vivo. Magn Reson Med 1991; 19: 489–495.
- 149 Rothman DL, Sibson NR, Hyder F, Shen J, Behar KL, Shulman RG. In vivo nuclear magnetic resonance spectroscopy studies of the relationship between the glutamate-glutamine neurotransmitter cycle and functional neuroenergetics [In Process Citation]. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1165–1177.
- 150 Yudkoff M, Nissim I, Daikhin Y, Lin ZP, Nelson D, Pleasure D, Erecinska M. Brain glutamate metabolism: neuronal-astroglial relationships. Dev Neurosci 1993; 15: 343–350.
- 151 Ross BD, Bluml S. New aspects of brain physiology. NMR Biomed 1996; 9: 279–296.
10.1002/(SICI)1099-1492(199610)9:7<279::AID-NBM435>3.0.CO;2-V CASPubMedWeb of Science®Google Scholar
- 152 Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 1996; 7: 1397–1400.
- 153 Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 1996; 111: 209–219.
- 154 Dijkhuizen RM, de Graaf RA, Tulleken KA, Nicolay K. Changes in the diffusion of water and intracellular metabolites after excitotoxic injury and global ischemia in neonatal rat brain. J Cereb Blood Flow Metab 1999; 19: 341–349.
- 155 Makris N, Worth AJ, Sorensen AG, Papadimitriou GM, Wu O, Reese TG, Wedeen VJ, Davis TL, Stakes JW, Caviness VS, Kaplan E, Rosen BR, Pandya DN, Kennedy DN. Morphometry of in vivo human white matter association pathways with diffusion-weighted magnetic resonance imaging. Ann Neurol 1997; 42: 951–962.
- 156 Pierpaoli C, Jezzard P, Basser PJ, Barnett A, Di Chiro G. Diffusion tensor MR imaging of the human brain. Radiology 1996; 201: 637–648.
- 157 Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, Rudge P, McDonald WI. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990; 113: 1477–1489.
- 158 Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991; 17: 357–367.
- 159 Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology 1993; 43: 697–700.
- 160 Ordidge RJ, Gorell JM, Deniau JC, Knight RA, Helpern JA. Assessment of relative brain iron concentrations using T2-weighted and T
-weighted MRI at 3 Tesla. Magn Reson Med 1994; 32: 335–341.
- 161 Ye FQ, Martin WR, Allen PS. Estimation of brain iron in vivo by means of the interecho time dependence of image contrast. Magn Reson Med 1996; 36: 153–158.
- 162 Kwong KK, Belliveau JW, Chesler DA, Goldberg IE, Weisskoff RM, Poncelet BP, Kennedy DN, Hoppel BE, Cohen MS, Turner R, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci USA 1992; 89: 5675–5679.
- 163 Ogawa S, Tank DW, Menon R, Ellermann JM, Kim SG, Merkle H, Ugurbil K. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci USA 1992; 89: 5951–5955.
- 164 Bartenstein P, Weindl A, Spiegel S, Boecker H, Wenzel R, Ceballos-Baumann AO, Minoshima S, Conrad B. Central motor processing in Huntington's disease. A PET study. Brain 1997; 120 (Pt 9): 1553–1567.
- 165 Belliveau JW, Kennedy DN Jr, McKinstry RC, Buchbinder BR, Weisskoff RM, Cohen MS, Vevea JM, Brady TJ, Rosen BR. Functional mapping of the human visual cortex by magnetic resonance imaging. Science 1991; 254: 716–719.
- 166 Detre JA, Leigh JS, Williams DS, Koretsky AP. Perfusion imaging. Magn Reson Med 1992; 23: 37–45.
- 167 Nguyen TV, Brownell AL, Iris Chen YC, Livni E, Coyle JT, Rosen BR, Cavagna F, Jenkins BG. Detection of the effects of dopamine receptor supersensitivity using pharmacological MRI and correlations with PET. Synapse 2000; 36: 57–65.
- 168 Dautry C, Conde F, Brouillet E, Mittoux V, Beal MF, Bloch G, Hantraye P. Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol Dis 1999; 6: 259–268.
- 169 Koga K, Mori A, Ohashi S, Kurihara N, Kitagawa H, Ishikawa M, Mitsumoto Y, Nakai M. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice. Eur J Neurosci 2006; 23: 1077–1081.
- 170 Pioro EP, Wang Y, Moore JK, Ng TC, Trapp BD, Klinkosz B, Mitsumoto H. Neuronal pathology in the wobbler mouse brain revealed by in vivo proton magnetic resonance spectroscopy and immunocytochemistry. Neuroreport 1998; 9: 3041–3046.
Citing Literature
